entertainment -WSS

entertainment

author：fashion 2025-10-01 15:27:57 - browse：255

A follow-up study of a first-of-its-kind cancer treatment may reflect systemic biases, the Food and Drug Administration said ahead of an advisory committee meeting Thursday to determine whether the drug should remain on the market.

The treatment, Lumakras, is designed to treat lung cancer caused by a specific genetic mutation to a protein called KRAS. It’s one of the most common genetic mutations in cancer, but repeated clinical trial failures had led researchers to deem it “undruggable” until a glimmer of hope came about a decade ago.

Lumakras received an accelerated, or conditional, approval in May 2021, making it the first KRAS drug on the market. Now, the drug’s manufacturer, Amgen, needs to prove it works.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Chan Zuckerberg Biohub Chicago to focus on inflammation

leisure time

WSS

With trial win, GSK could get blood cancer drug back on market

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

Letters to First Opinion on caregivers, digital health, and more

Bristol 'take

Why Charlie Gard's case is so disturbing to Americans

Why Charlie Gard's case is so disturbing to Americans

focus

entertainment

knowledge

Jerome Adams on the need for new antivirals for Covid

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

What does generative AI mean for health care? We asked experts

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

Medical leaders decry Supreme Court decision on affirmative action

Intellia reports positive results for its CRISPR

How to save PrEP access — and even expand it

FDA authorizes Novavax’s updated Covid

Dobbs anniversary: the lost opportunity of abortion as health care

The Pandemic Treaty must support building strong health systems

entertainment

Histogen: Failed biotech offers rare public look inside

Change Healthcare can notify patients about the breach, HHS says

FDA panel signals lack of confidence in Amgen cancer drug data

Woman returns to dialysis after doctors remove transplanted pig kidney

When women are denied an abortion, their children fare worse than peers

See how much Covid

leisure time

knowledge

hotspot

focus